FDA’s Jenkins On “Progressive Approval”: Don’t Lower The Efficacy Bar
This article was originally published in Pharmaceutical Approvals Monthly
Office of New Drugs director says a “weight of the evidence” standard will not provide reasonable assurance of drug efficacy and safety.
You may also be interested in...
Legislation being drafted by Sen. Kay Hagan, D-N.C., would formalize FDA practices of approving drugs in certain circumstances where the evidence needed for a standard approval cannot be generated.
Division of Mitigation Assessment and Medication Error Surveillance will be established within the Office of Surveillance and Epidemiology, a change aimed at strengthening postmarketing oversight of opioids and other drugs; new Office of Safety and Clinical Evaluation will be created in Office of Generic Drugs, where Orange Book staff also will get their own division.